Epi-On Corneal Crosslinking for Keratoconus

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 18, 2017

Primary Completion Date

September 1, 2019

Study Completion Date

September 30, 2019

Conditions
KeratoconusKeratoconus, Unstable
Interventions
DRUG

Riboflavin 5'-Phosphate

Photrexa (riboflavin 5'-phosphate ophthalmic solution) 0.146%, is a yellow sterile buffered solution containing 1.46 mg/mL riboflavin 5'-phosphate, The pH of the solution is approximately 7.1 and the osmolarity is 157-177 mOsm/kg. Each 1 mL of the solution contains 1.53 mg of riboflavin 5'-phosphate sodium (equivilant to 1.20 mg \[0.12%\] riboflavin). Riboflavin 5'-phosphate sodium USP is a mixture of the sodium salts of riboflavin, riboflavin monophosphates, and riboflavin diphosphates. The inactive ingredients are dibasic sodium phosphate, monbasic sodium phosphate, sodium chloride, and water for injection.

Trial Locations (1)

43082

Comprehensive EyeCare of Central Ohio, Westerville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Glaukos Corporation

INDUSTRY

lead

Comprehensive EyeCare of Central Ohio

OTHER

NCT03245853 - Epi-On Corneal Crosslinking for Keratoconus | Biotech Hunter | Biotech Hunter